UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
Clinical trials for UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stomach cancer: experimental drug pumitamig faces off against standard therapy
Disease control Recruiting nowThis study compares a new drug called pumitamig combined with chemotherapy against the standard treatment (nivolumab plus chemotherapy) for people with advanced or metastatic stomach, gastroesophageal junction, or esophageal cancer that hasn't been treated yet. About 690 particip…
Matched conditions: UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
New combo therapy aims to fight Hard-to-Treat stomach cancers
Disease control Recruiting nowThis study tests a new medicine (PF-08634404) combined with chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new combo t…
Matched conditions: UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 11, 2026 20:40 UTC